Skip to main content

Upstream Bio, Inc.

For the period ended Jun 30, 2025. Filed Aug 6, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 6, 2025

UPB$3.38-5.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Amounts in thousands, except share and per share amounts)

Three Months Ended June 30,Six Months Ended June 30,
2025202420252024
Collaboration revenue$937$510$1,503$1,150
Operating expenses:
Research and development37,86514,06963,66225,760
General and administrative7,4193,98114,2017,943
Total operating expenses45,28418,05077,86333,703
Loss from operations(44,347)(17,540)(76,360)(32,553)
Other income (expense):
Change in fair value of preferred stock tranche right liability———2,859
Interest income4,4312,8779,1744,143
Other expense, net(50)(15)(50)(21)
Total other income, net4,3812,8629,1246,981
Net loss$(39,966)$(14,678)$(67,236)$(25,572)
Redeemable convertible preferred stock cumulative dividends—(4,884)—(8,000)
Net loss attributable to common stockholders$(39,966)$(19,562)$(67,236)$(33,572)
Net loss per share attributable to common stockholders, basic and diluted$(0.74)$(6.50)$(1.25)$(11.18)
Weighted-average common shares outstanding, basic and diluted53,770,8683,008,80753,694,4243,002,173
Comprehensive loss:
Net loss$(39,966)$(14,678)$(67,236)$(25,572)
Unrealized gain (loss) on investments, net of tax(110)(34)283(76)
Total other comprehensive income (loss)(110)(34)283(76)
Comprehensive loss$(40,076)$(14,712)$(66,953)$(25,648)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.